Evidence map›Paper›PMID 26451657›Full record

ArticleAnalytical chemistry2015

Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum.

Stefani N Thomas, Robert Harlan, Jing Chen, Paul Aiyetan, Yansheng Liu, Lori J Sokoll, Ruedi Aebersold, Daniel W Chan, Hui Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytical chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Mass Spectrometry-Based Glycoproteomics and Prostate Cancer.International journal of molecular sciences · 2021
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Stefani N ThomasDepartment of Pathology, Clinical Chemistry Division, Johns Hopkins University School of Medicine , 1550 Orleans Street, CRBII Room 3M03, Baltimore, Maryland 21231, United States.
Robert HarlanDepartment of Pathology, Clinical Chemistry Division, Johns Hopkins University School of Medicine , 1550 Orleans Street, CRBII Room 3M03, Baltimore, Maryland 21231, United States.
Jing ChenDepartment of Pathology, Clinical Chemistry Division, Johns Hopkins University School of Medicine , 1550 Orleans Street, CRBII Room 3M03, Baltimore, Maryland 21231, United States.
Paul AiyetanDepartment of Pathology, Clinical Chemistry Division, Johns Hopkins University School of Medicine , 1550 Orleans Street, CRBII Room 3M03, Baltimore, Maryland 21231, United States.
Yansheng LiuDepartment of Biology, Institute of Molecular Systems Biology, ETH Zurich , 8093 Zurich, Switzerland.
Lori J SokollDepartment of Pathology, Clinical Chemistry Division, Johns Hopkins University School of Medicine , 1550 Orleans Street, CRBII Room 3M03, Baltimore, Maryland 21231, United States.
Ruedi AebersoldDepartment of Biology, Institute of Molecular Systems Biology, ETH Zurich , 8093 Zurich, Switzerland.
Daniel W ChanDepartment of Pathology, Clinical Chemistry Division, Johns Hopkins University School of Medicine , 1550 Orleans Street, CRBII Room 3M03, Baltimore, Maryland 21231, United States.
Hui ZhangDepartment of Pathology, Clinical Chemistry Division, Johns Hopkins University School of Medicine , 1550 Orleans Street, CRBII Room 3M03, Baltimore, Maryland 21231, United States.
Johns Hopkins University · USJohns Hopkins Medicine · USETH Zurich · CHUniversity of Zurich · CH

Funding

Shared Resource CoresP01HL107153 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HART, GERALD WARREN · 2011 to 2017
$16.8M
Proteome Characterization Center: A Genoproteomics Pipeline for Cance ResearchU24CA160036 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2011 to 2016
$10.7M
Clinical and Analytical Validation of Cancer BiomarkersU24CA115102 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI · 2005 to 2021
$7.4M
Glycoprotein biomarkers for the early detection of aggressive prostate cancerU01CA152813 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZHANG, HUI · 2010 to 2021
$6.2M
NCI NIH HHS U01 CA152813NCI NIH HHS U01CA152813NCI NIH HHS U24 CA115102NCI NIH HHS U24CA115102NCI NIH HHS U24 CA160036NCI NIH HHS U24CA160036NHLBI NIH HHS N01-HV-00240NHLBI NIH HHS P01 HL107153NHLBI NIH HHS P01HL107153
6 · The paper itself

Abstract

Protein glycosylation is one of the most common protein modifications, and the quantitative analysis of glycoproteins has the potential to reveal biological functions and their association with disease. However, the high throughput accurate quantification of glycoproteins is technically challenging due to the scarcity of robust assays to detect and quantify glycoproteins. Here we describe the development of multiplexed targeted MS assays to quantify N-linked glycosite-containing peptides in serum using parallel reaction monitoring (PRM). Each assay was characterized by its performance metrics and criteria established by the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (NCI CPTAC) to facilitate the widespread adoption of the assays in studies designed to confidently detect changes in the relative abundance of these analytes. An in-house developed software program, MRMPlus, was used to compute assay performance parameters including specificity, precision, and repeatability. We show that 43 selected N-linked glycosite-containing peptides identified in prostate cancer tissue studies carried out in our group were detected in the sera of prostate cancer patients within the quantitative range of the developed PRM assays. A total of 41 of these formerly N-linked glycosite-containing peptides (corresponding to 37 proteins) were reproducibly quantified based on their relative peak area ratios in human serum during PRM assay development, with 4 proteins showing differential significance in serum from nonaggressive (NAG) vs aggressive (AG) prostate cancer patient serum (n = 50, NAG vs AG). The data demonstrate that the assays can be used for the high throughput and reproducible quantification of a panel of formerly N-linked glycosite-containing peptides. The developed assays can also be used for the quantification of formerly N-linked glycosite-containing peptides in human serum irrespective of disease state.

Indexed as

AgedChromatography, LiquidGlycosylationHumansMaleMass SpectrometryMiddle AgedPeptidesProstatic NeoplasmsPeptides

Identifiers

PMID26451657
PMCPMC4708883
OpenAlexW2293031179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.